Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Assessing Our Progress and Looking Ahead
Posted on April 21st, 2017 by Ross Bersot, CFA in The Hive
Like many start-ups, Reset Therapeutics has been driven by big ideas, which we have pursued with passion, commitment and accountability. I think if you asked our Board and investors, we can clearly demonstrate we have met almost all of our timelines and milestones on budget. Following a plan for an NCE that was drawn on the back of a napkin five years ago through IND-enabling studies has been very exciting and rewarding for our entire team. We have a great group of problem solvers and creative thinkers who make this possible every day. Nothing is perfect and we’ve had some delays for unforeseen reasons, but our management team understands the drug discovery process and plans accordingly.
As we look ahead, we have the benefit and responsibility of choosing between a number of therapeutic indications and patient populations for our human POC studies with cryptochrome modulators. Elsevier’s solutions will continue to be an asset as they allow us to most effectively define our path forward by providing literature related to disease pathology and trial design parameters for previously-approved agents in the indications of interest and also experimental compounds currently moving through the clinical process.
Thinking about our goals for 2017, we expect to be in the clinic with our cryptochrome modulator program this year; pre-clinical data suggests the possibility of a meaningful advance in the treatment of hypercortisolism, type-II diabetes and inflammatory diseases, like rheumatoid arthritis. As a patient-focused company, we are very excited about the opportunity to give physicians and patients a new option by restoring healthy circadian rhythms and addressing multiple pathophysiologies associated with these diseases.
All opinions shared in this post are the author’s own.
R&D Solutions for Pharma & Life SciencesWe're happy to discuss your needs and show you how Elsevier's Solution can help.
Ross Bersot, CFA
President and CEO, Reset Therapeutics
- AI in Drug Discovery Has Great Potential – But Also Significant Barriers
- Emulating start-up success with purpose-built data tools
- Finding Answers Where You Least Expect Them
- Machine Learning Could Make Drug Discovery Faster, Cheaper, Better
- AI Can Work Wonders, But Can It Create Miracle Cures?